| |
 |
| |
 |
The
processing of the amyloid precursor
protein (APP) by membrane bound proteases
(‘secretases’) plays a crucial
role in the pathogenesis of Alzheimer’s
disease (AD) since it leads to the formation
of the proteolytic fragment Ab42, which
plays an early and crucial role in the
development of AD.
Because Ab42 generation is the first
step in the cascade, shutting down or
reducing its production by inhibiting
the key proteases involved in the process
should lead to effective disease treatment.
Thus, the identification of small molecule
secretase inhibitors should result in
disease-modifying therapy for treatment
of AD. |
| |
| |
| |
|
|
|
|
|
